Respirana, Inc was formed in March of 2020 by a team of commercially experienced medical device professionals to address the emergent need for large quantities of emergency ventilators in the early days of COVID-19 pandemic.

We quickly developed a first-generation emergency ventilator that is extremely easy-to-use and very inexpensive to produce, based a unique modular device platform. The existing market for ventilators going into the pandemic included the most basic offerings at $5k per unit and up, with full functioning critical care ventilators costing much more. Our device can be manufactured and sold at scale for less than $2k with a healthy gross margin. It is an ideal solution for rapid and cost-effective expansion of emergency and crisis surge capacity. As the COVID-19 needs for ventilators globally came well under control by mid-year, we turned our attention to the most relevant clinical and commercial applications for our novel design.

We have recently discovered a ve...
Respirana, Inc was formed in March of 2020 by a team of commercially experienced medical device professionals to address the emergent need for large quantities of emergency ventilators in the early days of COVID-19 pandemic.

We quickly developed a first-generation emergency ventilator that is extremely easy-to-use and very inexpensive to produce, based a unique modular device platform. The existing market for ventilators going into the pandemic included the most basic offerings at $5k per unit and up, with full functioning critical care ventilators costing much more. Our device can be manufactured and sold at scale for less than $2k with a healthy gross margin. It is an ideal solution for rapid and cost-effective expansion of emergency and crisis surge capacity. As the COVID-19 needs for ventilators globally came well under control by mid-year, we turned our attention to the most relevant clinical and commercial applications for our novel design.

We have recently discovered a very exciting and compelling “first-mover” use application for our technology in advanced CPR, and we are collaborating with a strategic partner in this field to produce improved outcomes and lives saved. In the long-term, we have a "dual market" value proposition – with a compelling clinical and commercial value propositions in developed health care systems, but with our low-cost elemental approach also present attractive large scale “impact” solutions for under-resourced health care countries/environments. In developed health care systems, our first-generation device will present the easiest, best and most cost-effective way to replace issue-prone manual resuscitation of critical patients (especially during advanced CPR, delivering improved outcomes). Further development of our low-cost platform will present the best way for under-resourced health care environments around the globe to get critical emergency ventilation in a wide range of use-cases, as many developing areas representing a large portion of the world’s population still suffer from a serious lack of critical care ventilators.

To date, with self-funding, we have designed, built, and tested multiple prototypes and successfully demonstrated safety and effectiveness in numerous animal studies. We are currently refining designs for pilot production and testing to build our 501k submission with the FDA. We have recently initiated efforts to raise seed capital and are gaining traction.
More information

Employees

Tom Hillman
Admin
Tom Hillman CEO 30+ year executive, corporate finance, strategy and planning background growing into more ops and gen management roles. 4 yrs med device.